SCHEMBL2002220

SCHEMBL2002220

CC1(CO)CCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29441195 1.00
SCHEMBL10876938 0.93
SCHEMBL16369916 0.91 MAPT (0.32)
SCHEMBL16369918 0.91 MAPT (0.32)
SCHEMBL16369919 0.91 MAPT (0.32)
SCHEMBL2810066 0.81
SCHEMBL29813212 0.81
SCHEMBL15568681 0.81
SCHEMBL29147410 0.79
SCHEMBL12011138 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119954990-A Titanium catalyst component for ethylene polymerization, catalyst, preparation and application thereof 中国石油化工股份有限公司 2025-05-09 CN claimed
CN-119954990-A Titanium catalyst component for ethylene polymerization, catalyst, preparation and application thereof 中国石油化工股份有限公司 2025-05-09 CN disclosed
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 EP disclosed
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 US disclosed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 US disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
EP-4329757-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2024-03-06 EP disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
US-8598155-B2 Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders PFIZER INC. (US) 2013-12-03 US disclosed
WO-2013061004-A1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-05-02 WO disclosed
WO-2013061004-A1 NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-05-02 WO disclosed
CN-102822172-A Substituted naphthyridines and their use as syk kinase inhibitors BOEHRINGER INGELHEIM INT 2012-12-12 CN disclosed
US-20120214791-A1 Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders PFIZER INC. 2012-08-23 US disclosed
US-7960407-B2 Crystal forms of an imidazole derivative REQUALIA PHARMA INC. (JP) 2011-06-14 US disclosed
EP-1861400-B1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE RAQUALIA PHARMA INC (JP) 2010-05-26 EP disclosed
US-20090018158-A1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE ASKAT INC. (JP) 2009-01-15 US disclosed
EP-1861400-A1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE Pfizer, Inc. (US) 2007-12-05 EP disclosed
WO-2006095268-A1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE PFIZER JAPAN INC. (JP) 2006-09-14 WO disclosed